MedPath

Gliadel

These highlights do not include all the information needed to use GLIADEL WAFER safely and effectively. See full prescribing information for GLIADEL WAFER. GLIADEL WAFER (carmustine implant), for intracranial useInitial U.S. Approval: 1996

Approved
Approval ID

38962a55-a514-4c48-bea5-f99a8da4beec

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 13, 2018

Manufacturers
FDA

Arbor Pharmaceuticals

DUNS: 781796417

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

carmustine

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code24338-050
Application NumberNDA020637
Product Classification
M
Marketing Category
C73594
G
Generic Name
carmustine
Product Specifications
Route of AdministrationINTRACAVITARY
Effective DateDecember 13, 2018
FDA Product Classification

INGREDIENTS (2)

carmustineActive
Quantity: 7.7 mg in 1 1
Code: U68WG3173Y
Classification: ACTIB
polifeprosan 20Inactive
Code: S40C40DA21
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Gliadel - FDA Drug Approval Details